


## Bemfivastatin hemicalcium

Cat. No.:	HY-106281A
CAS No.:	805241-64-9
Molecular Formula:	C <sub>34</sub> H <sub>37</sub> FN <sub>2</sub> O <sub>6</sub> ·1/2Ca
Molecular Weight:	607.74
Target:	HMG-CoA Reductase (HMGCR)
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### BIOLOGICAL ACTIVITY

#### Description

Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of  $\geq 320$  mg/kg/d (rat developmental toxicity),  $\geq 12.5$  mg/kg/d (rabbit maternal toxicity),  $\geq 25$  mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.

### REFERENCES

[1]. Faqi AS, et al. Developmental toxicity of the HMG-CoA reductase inhibitor (PPD10558) in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):23-37.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA